How Cancer Patients At Different Stages Use Tukysa?

How Cancer Patients At Different Stages Use Tukysa?

TUKYSA is a cancer medicine that is used to treat breast cancer that is locally advanced or metastatic (has spread to other parts of the body) and when it is HER2-positive. This means the cancer cells produce a protein on their surface, HER2, which stimulates the growth of the cancer.

TUKYSA is used with two other medicines, capecitabine and trastuzumab, and is used after at least 2 other treatments for HER2-positive cancer have already been tried.

The active substance in TUKYSA is tucatinib. Please see full indication & Important Facts.


What is TUKYSA cancer treatment?

TUKYSA is a cancer medication prescribed for the treatment of locally advanced or metastatic breast cancer that is HER2-positive. In such cases, cancer cells produce a surface protein known as HER2, which triggers the growth of the cancer. TUKYSA is specifically designed to target and address this HER2-positive breast cancer.

How effective is TUKYSA?

39.7% (135 out of 340) of individuals experienced tumor shrinkage with TUKYSA, as opposed to 21.6% (37 out of 171) of individuals who underwent treatment with trastuzumab and capecitabine alone. In the TUKYSA* group, 0.9% (3 of 340) of participants achieved a complete response, indicating the complete disappearance of tumors, compared to 1.2% (2 of 171) in the trastuzumab-treated group.

The trial findings underscored that, after 1 year of follow-up, the risk of progression or death was significantly reduced by 46% in the group receiving tucatinib in combination with trastuzumab and capecitabine compared to the placebo group (Hazard Ratio [HR]: 0.54; 95% CI: 0.42–0.71).

Is TUKYSA FDA approved?

On January 19, 2023, the Food and Drug Administration (FDA) provided accelerated approval to tucatinib (TUKYSA, Seagen Inc.) in combination with trastuzumab for the treatment of colorectal cancer.

How much does TUKYSA cost?

The price for a supply of 60 tablets of TUKYSA oral tablet 150 mg is approximately $13,504, with variations depending on the pharmacy you choose to visit.

TUKYSA(tucatinib) tablets Dosing

TUKYSA is taken orally, twice a day; The recommended dose of TUKYSA is 300 mg twice daily, taken 12 hours apart with or without food; Swallow tablets whole.

TUKYSA side effects

Individuals using this medication may experience symptoms such as nausea, vomiting, mouth sores or pain, loss of appetite, weight loss, tiredness, or muscle/joint pain. If any of these effects persist or worsen, it is advised to promptly inform your doctor or pharmacist. Notably, diarrhea is a frequent side effect, and in some cases, it may be severe. Continuous vomiting or diarrhea that does not subside may lead to dehydration. Should you encounter such persistent symptoms, seek medical attention promptly.